SN//Connect

Practical Guidance on Mental Health and Physician Burnout

Latest News

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Relevance: Tepotinib’s approval marks a pivotal advancement in targeted therapy for NSCLC, offering a highly specific treatment option for patients with MET exon 14 skipping mutations and underscoring the importance of genetic profiling in modern oncology practice. _________________________________________________________________________________________________ The availability of Tepmetko (tepotinib), should prompt ontologists to order genetic testing for all of their […]

Learn More

HER2-Low, A New Classification Of Breast Cancer, Expands The Use Of Enhertu For Metastatic Patients

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Trastuzumab deruxtecan (brand name: Enhertu) is a Food and Drug Administration (FDA) approved drug for certain stage four breast cancer patients whose tumors are classified as HER2- low. Previous therapies targeting cancer tumors with HER2 (Human Epidermal Growth Factor 2)-low proteins, such as trastuzumab (brand name: […]

Learn More

The Evolving Management of Anemia in Myelofibrosis

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Myelofibrosis (MF) belongs to a group of blood cancers called myeloproliferative neoplasms (MPNs). These cancers originate in the myeloid tissue, commonly known as the bone marrow, which lines the inside of large bones, such as the vertebral column or the hip bones. “The [abnormal] cell of […]

Learn More

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Mantle Cell Lymphomas (MCL) are rare blood cancers that affect the white blood cells (WBCs), one of the main cell types within the blood. These cancers are as aggressive as they are rare. Treating them can often prove to be an uphill battle. They often reoccur […]

Learn More

Elacestrant (Orserdu) Is Effective For A Stubborn Form of Metastatic Breast Cancer

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. For some women with a particular type of advanced, or metastatic, breast cancer, a new treatment option is showing really promising results. Metastatic breast cancer can be hard to treat, especially when some of the traditional hormone/endocrine therapies do not work. This may happen with particular […]

Learn More

Ibrutinib For Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a rare but deadly form of non-Hodgkin lymphoma, a blood cancer affecting the white blood cells (WBCs). It tends to be aggressive and is usually diagnosed later in the disease course, when it is often resistant to treatment. Traditional treatment with the best chance for long-term disease control for MCL […]

Learn More

When To Treat Chronic Lymphocytic Leukemia (CLL)?

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic Lymphocytic Leukemia (CLL) is a slow-going or “indolent” blood cancer. Despite being cancer, it is one of those counterintuitive diseases for which delaying treatment can surprisingly be the most appropriate “treatment” option. Studies show that many patients with this disease can live long, fulfilling lives […]

Learn More

Active Surveillance For Chronic Lymphocytic Leukemia (CLL)

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Chronic Lymphocytic Leukemia (CLL) is a slow-growing cancer of the white blood cells (WBCs). This specific type of cancer has great, effective treatment options Moreover, some patients, especially those in the early, asymptomatic stages of the disease, may be able to live for long periods of […]

Learn More